Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):431–439. doi: 10.1038/sj.bjc.6690712

Development of a novel bi-specific monoclonal antibody approach for tumour targeting

A A Koumarianou 1, M Hudson 1, R Williams 1, A A Epenetos 2, G W H Stamp 1
PMCID: PMC2362912  PMID: 10507767

Abstract

To overcome the disadvantages of bi-specific antibody methodologies in vivo, a novel antibody approach has been designed to improve tumour targeting and effector to target ratio. The technique involves biotinylated anti-CD3 Fab fragments and streptavidinylated anti-tumour monoclonal antibodies (mAbs) that can spontaneously form cross-links. We describe here a method for the direct cross-linking of sulphydryl-conjugated HMFG1 (anti-MUC1 mucin mAb) to streptavidin by sulphosuccinimidyl-4-(N-maleimidomethyl) cyclohexane- 1-carboxylate. Fab fragments generated by papain digestion of the 1452C11 antibody (anti-CD3 mAb without Fc to avoid peripheral activation of T-cells) were biotinylated with NHS-Iminobiotin. MUC1-transfected BALB/c breast cancer cell lines 413BCR and 425CCR and the parental cell line (410.4) were labelled with streptavidinylated mouse anti-MUC1 mucin mAb. BALB/c effector T-cells were separately labelled with biotinylated anti-CD3 Fab fragments (1452C11) and mixed with tumour cells in different effector to target ratios. Percentage of killing was assessed using the 51Cr cytotoxicity assay. Seventy per cent lysis was measured in the case of 413BCR (high MUC1 mucin expressor) and 40% in the case of 425CCR (low expressor) cell line. No lysis was apparent in the MUC1 negative cell line. These results demonstrate that the novel T-cell redirecting approach we have developed can produce effective immune lysis of target cells in vitro. © 1999 Cancer Research Campaign

Keywords: bi-specific monoclonal antibody, tumour immunotherapy, directly streptavidinylated antibody, biotinylated anti-CD3 Fab fragments, MUC1 mucin

Full Text

The Full Text of this article is available as a PDF (305.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anjaneyulu P. S., Staros J. V. Reactions of N-hydroxysulfosuccinimide active esters. Int J Pept Protein Res. 1987 Jul;30(1):117–124. doi: 10.1111/j.1399-3011.1987.tb03319.x. [DOI] [PubMed] [Google Scholar]
  2. Batra S. K., Kern H. F., Worlock A. J., Metzgar R. S., Hollingsworth M. A. Transfection of the human Muc 1 mucin gene into a poorly differentiated human pancreatic tumor cell line, Panc1: integration, expression and ultrastructural changes. J Cell Sci. 1991 Dec;100(Pt 4):841–849. doi: 10.1242/jcs.100.4.841. [DOI] [PubMed] [Google Scholar]
  3. Blazar B. A., Laing C. A., Miller F. R., Heppner G. H. Activity of lymphoid cells separated from mammary tumors in blastogenesis and Winn assays. J Natl Cancer Inst. 1980 Aug;65(2):405–410. [PubMed] [Google Scholar]
  4. Brunner K. T., Mauel J., Cerottini J. C., Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968 Feb;14(2):181–196. [PMC free article] [PubMed] [Google Scholar]
  5. Demanet C., Brissinck J., Moser M., Leo O., Thielemans K. Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer Suppl. 1992;7:67–68. [PubMed] [Google Scholar]
  6. Devine P. L., McKenzie I. F. Mucins: structure, function, and associations with malignancy. Bioessays. 1992 Sep;14(9):619–625. doi: 10.1002/bies.950140909. [DOI] [PubMed] [Google Scholar]
  7. Duncan R. J., Weston P. D., Wrigglesworth R. A new reagent which may be used to introduce sulfhydryl groups into proteins, and its use in the preparation of conjugates for immunoassay. Anal Biochem. 1983 Jul 1;132(1):68–73. doi: 10.1016/0003-2697(83)90426-8. [DOI] [PubMed] [Google Scholar]
  8. ELLMAN G. L. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70–77. doi: 10.1016/0003-9861(59)90090-6. [DOI] [PubMed] [Google Scholar]
  9. Epenetos A. A., Britton K. E., Mather S., Shepherd J., Granowska M., Taylor-Papadimitriou J., Nimmon C. C., Durbin H., Hawkins L. R., Malpas J. S. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  10. George A. J., Titus J. A., Jost C. R., Kurucz I., Perez P., Andrew S. M., Nicholls P. J., Huston J. S., Segal D. M. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J Immunol. 1994 Feb 15;152(4):1802–1811. [PubMed] [Google Scholar]
  11. Gilliland L. K., Clark M. R., Waldmann H. Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7719–7723. doi: 10.1073/pnas.85.20.7719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Green N. M. Avidin. Adv Protein Chem. 1975;29:85–133. doi: 10.1016/s0065-3233(08)60411-8. [DOI] [PubMed] [Google Scholar]
  13. Haagen I. A., Geerars A. J., de Lau W. B., Bast B. J., de Gast B. C. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood. 1995 Jun 1;85(11):3208–3212. [PubMed] [Google Scholar]
  14. Hashida S., Imagawa M., Inoue S., Ruan K. H., Ishikawa E. More useful maleimide compounds for the conjugation of Fab' to horseradish peroxidase through thiol groups in the hinge. J Appl Biochem. 1984 Feb-Apr;6(1-2):56–63. [PubMed] [Google Scholar]
  15. Havran W. L., Allison J. P. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature. 1988 Sep 29;335(6189):443–445. doi: 10.1038/335443a0. [DOI] [PubMed] [Google Scholar]
  16. Heppner G. H., Dexter D. L., DeNucci T., Miller F. R., Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978 Nov;38(11 Pt 1):3758–3763. [PubMed] [Google Scholar]
  17. Hnatowich D. J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987 Aug;28(8):1294–1302. [PubMed] [Google Scholar]
  18. Kalofonos H. P., Rusckowski M., Siebecker D. A., Sivolapenko G. B., Snook D., Lavender J. P., Epenetos A. A., Hnatowich D. J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med. 1990 Nov;31(11):1791–1796. [PubMed] [Google Scholar]
  19. Laemmli U. K., Beguin F., Gujer-Kellenberger G. A factor preventing the major head protein of bacteriophage T4 from random aggregation. J Mol Biol. 1970 Jan 14;47(1):69–85. doi: 10.1016/0022-2836(70)90402-x. [DOI] [PubMed] [Google Scholar]
  20. Le Doussal J. M., Barbet J., Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int J Cancer Suppl. 1992;7:58–62. [PubMed] [Google Scholar]
  21. Leo O., Foo M., Sachs D. H., Samelson L. E., Bluestone J. A. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1374–1378. doi: 10.1073/pnas.84.5.1374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Miller B. E., Miller F. R., Machemer T., Heppner G. H. Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour. Br J Cancer. 1993 Jul;68(1):18–25. doi: 10.1038/bjc.1993.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nicoletti I., Migliorati G., Pagliacci M. C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991 Jun 3;139(2):271–279. doi: 10.1016/0022-1759(91)90198-o. [DOI] [PubMed] [Google Scholar]
  24. Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990 Feb 17;335(8686):368–371. doi: 10.1016/0140-6736(90)90205-j. [DOI] [PubMed] [Google Scholar]
  25. Paganelli G., Riva P., Deleide G., Clivio A., Chiolerio F., Scassellati G. A., Malcovati M., Siccardi A. G. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer Suppl. 1988;2:121–125. doi: 10.1002/ijc.2910410727. [DOI] [PubMed] [Google Scholar]
  26. Perez P., Hoffman R. W., Shaw S., Bluestone J. A., Segal D. M. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul 25;316(6026):354–356. doi: 10.1038/316354a0. [DOI] [PubMed] [Google Scholar]
  27. Portoles P., Rojo J., Golby A., Bonneville M., Gromkowski S., Greenbaum L., Janeway C. A., Jr, Murphy D. B., Bottomly K. Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation. J Immunol. 1989 Jun 15;142(12):4169–4175. [PubMed] [Google Scholar]
  28. Soule H. D., Vazguez J., Long A., Albert S., Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973 Nov;51(5):1409–1416. doi: 10.1093/jnci/51.5.1409. [DOI] [PubMed] [Google Scholar]
  29. Staerz U. D., Kanagawa O., Bevan M. J. Hybrid antibodies can target sites for attack by T cells. Nature. 1985 Apr 18;314(6012):628–631. doi: 10.1038/314628a0. [DOI] [PubMed] [Google Scholar]
  30. Taylor-Papadimitriou J., Epenetos A. A. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol. 1994 Jun;12(6):227–233. doi: 10.1016/0167-7799(94)90121-X. [DOI] [PubMed] [Google Scholar]
  31. Weiner G. J., Kostelny S. A., Hillstrom J. R., Cole M. S., Link B. K., Wang S. L., Tso J. Y. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 1994 Mar 1;152(5):2385–2392. [PubMed] [Google Scholar]
  32. Zhu H., Jain R. K., Baxter L. T. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med. 1998 Jan;39(1):65–76. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES